Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The impact on outcome of the addition of all- trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1 , FLT3 , and CEBPA

Alan K. Burnett, Robert K. Hills, Claire Green, Sarah Jenkinson, Kenneth Koo, Yashma Patel, Carol Guy, Amanda Gilkes, Donald W. Milligan, Anthony H. Goldstone, Archibald G. Prentice, Keith Wheatley, David C. Linch, Rosemary E. Gale

Blood (2010) 115 (5): 948–956.

https://doi.org/10.1182/blood-2009-08-236588

Published: 2010

Includes: Supplemental data

Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock

Blood (2009) 114 (22): 3428.

https://doi.org/10.1182/blood.V114.22.3428.3428

Published: 2009

Journal Articles

Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?

Julio Delgado, Donald W. Milligan, Peter Dreger

Blood (2009) 114 (13): 2581–2588.

https://doi.org/10.1182/blood-2009-05-206821

Published: 2009

Journal Articles

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Donald W. Milligan, Keith Wheatley, Timothy Littlewood, Jenny I. O. Craig, Alan K. Burnett, for the NCRI Haematological Oncology Clinical Studies Group

Blood (2006) 107 (12): 4614–4622.

https://doi.org/10.1182/blood-2005-10-4202

Published: 2006

Journal Articles

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

Julio Delgado, Kirsty Thomson, Nigel Russell, Joanne Ewing, Wendy Stewart, Gordon Cook, Stephen Devereux, Richard Lovell, Rajesh Chopra, David I. Marks, Stephen Mackinnon, Donald W. Milligan

Blood (2006) 107 (4): 1724–1730.

https://doi.org/10.1182/blood-2005-08-3372

Published: 2006

Journal Articles

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Keith Wheatley, DPhil, Cassey L. Brookes, MSc, Robert K. Hills, DPhil, Anthony H. Goldstone, FRCP, Donald W. Milligan, MD, Archie G. Prentice, Anthony V. Moorman, PhD, Alan K. Burnett

Blood (2005) 106 (11): 674.

https://doi.org/10.1182/blood.V106.11.674.674

Published: 2005

Journal Articles

Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.

Alan K. Burnett, MD, Donald W. Milligan, MD, Archie G. Prentice, MB, Anthony H. Goldstone, MD, Mary F. McMullin, MD, Robert K. Hills, PhD, Keith Wheatley, PhD

Blood (2005) 106 (11): 543.

https://doi.org/10.1182/blood.V106.11.543.543

Published: 2005

Journal Articles

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

Donald W. Milligan, Savio Fernandes, Ranjit Dasgupta, Faith E. Davies, Estella Matutes, Christopher D. Fegan, Christopher McConkey, J. Anthony Child, David Cunningham, Gareth J. Morgan, Daniel Catovsky, for the National Cancer Research Institute (NCRI) Haematological Studies Group

Blood (2005) 105 (1): 397–404.

https://doi.org/10.1182/blood-2004-01-0298

Published: 2005

Journal Articles

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia

Mark A. Cook, Donald W. Milligan, Christopher D. Fegan, Philip J. Darbyshire, Premini Mahendra, Charles F. Craddock, Paul A. H. Moss, David C. Briggs

Blood (2004) 103 (4): 1521–1526.

https://doi.org/10.1182/blood-2003-02-0438

Published: 2004

Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan

Blood (2003) 102 (13): 4277–4283.

https://doi.org/10.1182/blood-2003-05-1620

Published: 2003

Journal Articles

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

Suparno Chakrabarti, Donald W. Milligan, Deenan Pillay, Stephen Mackinnon, Kathleen Holder, Narinder Kaur, Dorothy McDonald, Christopher D. Fegan, Herman Waldmann, Geoff Hale, Alan Rickinson, Neil Steven

Blood (2003) 102 (3): 839–842.

https://doi.org/10.1182/blood.V102.3.839

Published: 2003

Journal Articles

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Blood (2002) 100 (9): 3108–3114.

https://doi.org/10.1182/blood-2002-02-0506

Published: 2002

Journal Articles

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery

Suparno Chakrabarti, Vivien Mautner, Husam Osman, Kathryn E. Collingham, Chris D. Fegan, Paul E. Klapper, Paul A. H. Moss, Donald W. Milligan

Blood (2002) 100 (5): 1619–1627.

https://doi.org/10.1182/blood-2002-02-0377

Published: 2002

Journal Articles

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis D. Kottaridis, Karl Peggs, Peter O'Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, Geoff Hale, Christopher D. Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald W. Milligan

Blood (2002) 99 (12): 4357–4363.

https://doi.org/10.1182/blood.V99.12.4357

Published: 2002

Journal Articles

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Blood (2002) 99 (3): 1071–1078.

https://doi.org/10.1182/blood.V99.3.1071

Published: 2002

Journal Articles

Role for CCG-trinucleotide repeats in the pathogenesis of chronic lymphocytic leukemia

Rebecca L. Auer, Christopher Jones, Roman A. Mullenbach, Denise Syndercombe-Court, Donald W. Milligan, Christopher D. Fegan, Finbarr E. Cotter

Blood (2001) 97 (2): 509–515.

https://doi.org/10.1182/blood.V97.2.509

Published: 2001

Journal Articles

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Blood (2000) 96 (7): 2419–2425.

https://doi.org/10.1182/blood.V96.7.2419

Published: 2000

Journal Articles

High Prevalence of Hepatitis G Virus in Bone Marrow Transplant Recipients and Patients Treated for Acute Leukemia

Susan J. Skidmore, Kathryn E. Collingham, Paul Harrison, Jeffrey R. Neilson, Deenan Pillay, Donald W. Milligan

Blood (1997) 89 (10): 3853–3856.

https://doi.org/10.1182/blood.V89.10.3853

Published: 1997

NARROW

The impact on outcome of the addition of all- trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1 , FLT3 , and CEBPA

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Role for CCG-trinucleotide repeats in the pathogenesis of chronic lymphocytic leukemia

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

High Prevalence of Hepatitis G Virus in Bone Marrow Transplant Recipients and Patients Treated for Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only